Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial

Table 2

Probability of developing CHD over 10 years: descriptive statistics and distribution of patients within estimated 10-year CHD risk categories, based on treated patients.

	T40/T80	T40/H12.5/T80/H25	Total
Total patients (N)	294	594	888
Overall probability of developing CHD over 10 years
Mean (SD)	9.06 (7.89)	7.66 (7.12)	8.12 (7.41)
Range (min–max)	0.35–51.06	0.04–49.39	0.04–51.06
Patients in CHD risk category, N (%)
CHD 1 (<10%)	187 (63.6)	446 (75.1)	633 (71.3)
CHD 2 (10–<20% )	77 (26.2)	109 (18.4)	186 (20.9)
CHD 3 (≥20%)	30 (10.2)	39 (6.6)	69 (7.8)

Percentages may not sum to 100% due to rounding.
CHD: coronary heart disease; H12.5: hydrochlorothiazide 12.5 mg; H25: hydrochlorothiazide 25 mg; SD: standard deviation; T40: telmisartan 40 mg; T80: telmisartan 80 mg.